Alembic Pharmaceuticals Gets USFDA Nod For Amantadine Hydrochloride Capsules


Alembic Pharmaceuticals on Thursday announced that it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amantadine Hydrochloride Capsules, USP, 100 mg.

Amantadine Hydrochloride Capsules are indicated for the treatment of Parkinsonism and drug-induced extrapyramidal reactions.

Meanwhile, Alembic Pharmaceuticals was trading up by 1.5% at Rs 540 per share at 0936 hours on BSE. It hit a high of Rs 543 and a low of Rs 538.05 so far during the morning session.

The stock has underperformed BSE Mid-cap and BSE Healthcare Index over a period of one year. Its closest peers are Alkem Laboratories and Torrent Pharmaceuticals.

Alembic Pharmaceuticals Limited is engaged in developing formulations and active pharmaceutical ingredients (API). The company focuses on therapies such as cardiology, diabetes, gynaecology, gastrointestinal, orthopaedic, dermatology and ophthalmology.

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: